Fimepinostat in Treating Younger Patients with Relapsed or Refractory Solid Tumors, Central Nervous System Tumors, or Lymphoma

Inclusion Criteria

• Karnofsky performance status >= 50% for patients >= 16 years of age and Lansky >= 50% for patients < 16 years of age
• For Parts A and B, participants must have evaluable or measurable disease
• For Part A, participants must have histologically confirmed solid tumors, CNS tumors, or lymphoma based upon biopsy or surgery at initial diagnosis and/or relapse/progression; the only exception to histologic confirmation is for pediatric tumors that are routinely diagnosed exclusively by standard clinical imaging criteria: diffuse intrinsic pontine glioma and optic pathway glioma
• For Part B, participants must have one of the following diagnoses histologically confirmed: * Neuroblastoma with evidence of mycn/myc positivity based on any of the following: ** MYCN amplification (> 4 copy amplification) from Children's Oncology Group (COG) reference laboratory or other Clinical Laboratory Improvement Act (CLIA)-certified laboratory; or ** Mycn protein expression >= 1+ according to validated assay in Children’s Hospital Los Angeles (CHLA) Clinical Pathology Laboratory; or ** Myc expression >= 1+ according to validated assay in CHLA Clinical Pathology Laboratory * One of the following mature B cell lymphoma diagnoses: ** Diffuse large B cell lymphoma ** Burkitt lymphoma * An extra-cranial, solid tumor, other than neuroblastoma, with evidence of MYC or MYCN-alteration based on either of the following: ** MYC or MYCN amplification from a CLIA-certified laboratory ** MYC or MYCN high copy gain from a CLIA-certified laboratory
• Participants must have disease that is relapsed or refractory and for which standard curative or palliative measures do not exist or are no longer effective
• Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy except organ function; patients must meet the following minimum washout periods prior to enrollment: * At least 14 days after the last dose of myelosuppressive chemotherapy (42 days for nitrosourea or mitomycin C) * Radiotherapy: ** At least 14 days after local palliative radiation therapy (XRT) (small port); ** At least 90 days must have elapsed after prior total body irradiation (TBI), craniospinal XRT or if > 50% radiation of pelvis; ** At least 42 must have elapsed if other substantial bone marrow (BM) radiation; ** At least 42 days must have passed since last iobenguane (MIBG) or other radionuclide therapy * At least 7 days following the last dose of a biologic agent; for agents with known adverse events occurring beyond 7 days, this duration must be extended beyond the time in which adverse events are known to occur; if extended duration is required, this should be discussed and approved by the study chair * Monoclonal antibody: At least 21 days must have elapsed after the last dose of antibody * At least 14 days following the last dose of long-acting growth factor (e.g. Neulasta) or 7 days following short-acting growth factor * The patient must have no evidence of graft versus host disease and at least 42 days must have elapsed after transplant, stem cell infusion, or cellular therapy * At least 3 weeks from prior major surgical procedure; Note: Biopsy and central line placement/removal are not considered major * The patient must not have received prior CUDC-907 therapy; prior treatment with individual PI3K or HDAC inhibitors is allowed; patients must not have received therapy with the combination of PI3K and HDAC inhibitors
• Absolute neutrophil count >= 1,000/uL
• Platelets >= 75,000/uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to complete blood count (CBC) documenting eligibility
• Total bilirubin =< 1.5 x upper limit of normal for age
• Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 135 U/L; for the purpose of this study, the upper limit of normal (ULN) for ALT is 45 U/L
• Serum albumin >= 2 g/dL
• A serum creatinine based on age/gender as follows: * 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female) * 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female) * 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female) * 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female) * 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female) * >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female) OR
• Creatinine clearance >= 70 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal
• Corrected QT interval (QTc) =< 480 msec
• Diarrhea < grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 4
• Fasting glucose < grade 2 (=< 160 mg/dL or =< 8.9 mmol/L) without the use of antihyperglycemic agents
• Patients must be able to swallow either intact capsules or mini-tabs without chewing
• In order to limit dose deviations due to rounding, patients must have a body surface area of at least 0.5 m^2
• For patients with CNS tumors (primary or metastatic), any baseline neurologic deficits (including seizure) must be stable for at least one week prior to study enrollment
• Ability to understand and/or the willingness of the patient (or parent or legally authorized representative, if minor) to provide informed consent, using an institutionally approved informed consent procedure

Exclusion Criteria

• Patients must not be receiving any of the following concomitant medications: * Pharmacologic doses of systemic corticosteroids unless for CNS metastatic or primary disease; for patients with CNS metastatic or primary tumors receiving corticosteroids, they should be on a stable or decreasing dose over the 7 days prior to registration; for all patients, receipt of systemic physiologic replacement steroids, topical, and/or inhaled corticosteroids is acceptable * Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparins
• Pregnant participants will not be entered on this study given that the effects of CUDC-907 on the developing human fetus are unknown
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CUDC-907, breastfeeding mothers are not eligible
• Participants of child-bearing or child-fathering potential must agree to use adequate contraception (hormonal birth control; intrauterine device; double barrier method; or total abstinence) throughout their participation, including up until 30 days after last dose of CUDC-907
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to CUDC-907
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; Note that patients who have had prior allogeneic transplantation are required to have cytomegalovirus (CMV) polymerase chain reaction (PCR) testing performed during screening; a positive screen would be evidence of an active infection and would render the patient ineligible
• Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening)
• Patients with a known history of type 1 or type 2 diabetes mellitus
• Patients with gastrointestinal disease or disorder that could interfere with absorption of CUDC-907, such as bowel obstruction or inflammatory bowel disease